Liver study tests safety of fexinidazole in 21 volunteers
NCT ID NCT05607173
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at how the drug fexinidazole, used for sleeping sickness, is processed by the body in people with mild or moderate liver impairment compared to those with normal liver function. Twenty-one adults took a single 1200 mg tablet, and researchers measured drug levels in the blood. The goal was to understand if liver problems change drug exposure, which could lead to updated safety guidelines.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fexinidazole
- What this could lead to
- If successful, this study could help determine safe dosing guidelines for fexinidazole in patients with liver impairment.
- What could go wrong
- This is a small, early-phase study with only 21 participants, so results may not apply broadly. The drug is currently contraindicated in liver impairment, and this study is exploratory.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC FUNCTION ABNORMAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational Site Number: 100-0001
Sofia, 1612, Bulgaria
-
Investigational site 250-0001
Rennes, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.